Company intelligence / Profile preview
ImmuXell Biotech
Shanghai, Shanghai, Chinaimmuxell.cn ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
ImmuXell Biotech is a clinical-stage company developing immune cell therapies, with its lead candidate IX001 currently in Phase 1 trials for advanced solid tumors driven by KRAS mutations. The company focuses on both personalized and universal TCR-based therapies to improve efficacy and accessibility of cell therapy for refractory malignancies. No published clinical results yet; the first trial began July 2024.[1][2][4][5]
- Therapeutic areas
- Oncology
- Modalities
- TCR-T cell therapySmall molecule drugsTCR fusion protein[1][2][5]
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
No major pharmaceutical partnerships disclosed. Clinical collaboration with Shanghai Pudong Hospital as trial site/sponsor.[1]
Beyond the preview
Go deeper on ImmuXell Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ImmuXell Biotech.